Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 176

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Tuberculosis drug discovery in the post‐post‐genomic era

Open access
Lechartier, Benoit, Rybniker, Jan, Zumla, Alimuddin, Cole, Stewart T · 2014 · EMBO Molecular Medicine

Abstract

The expectation that genomics would result in new therapeutic interventions for infectious diseases remains unfulfilled. In the post‐genomic era, the decade immediately following the availability of the genome sequence of M ycobacterium tuberculosis , tuberculosis ( TB ) drug discovery relied heavily on the target‐based approach but this proved unsuccessful leading to a return to whole cell screening. Genomics underpinned screening by providing knowledge and many enabling technologies, most importantly whole genome resequencing to find resistance mutations and targets, and this resulted in a selection of leads and new TB drug candidates that are reviewed here. Unexpectedly, many new targets were found to be ‘promiscuous’ as they were inhibited by a variety of different compounds. In the post‐post‐genomics era, more advanced technologies have been implemented and these include high‐content screening, screening for inhibitors of latency, the use of conditional knock‐down mutants for validated targets and si RNA screens. In addition, immunomodulation and pharmacological manipulation of host functions are being explored in an attempt to widen our therapeutic options.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/emmm.201201772

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 176

Metadata

Authors
Lechartier, B., Rybniker, J., Zumla, A., & Cole, S. T.
Venue
EMBO Molecular Medicine
Published
2014-01-08
Volume
6
Issue
2
Pages
158-168
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2122267877
Cited by
176
References
9
FWCI
17.09
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.